Ku ya 5 Nyakanga, Novo Nordisk yatangije icyiciro cya gatatu cy’amavuriro y’inshinge ya CagriSema mu Bushinwa, ikigamijwe ni ukugereranya umutekano n’akamaro ko guterwa CagriSema na semeglutide ku barwayi bafite umubyibuho ukabije kandi ufite ibiro byinshi mu Bushinwa.
Gutera CagriSema nubuvuzi bumaze igihe kinini buvurwa na Novo Nordisk, ibyingenzi ni GLP-1 (glucagon-isa na peptide-1) reseptor agonist smeglutide hamwe na amylin analog cagrilintide ikora.Gutera CagriSema birashobora gutangwa mu buryo bwihuse rimwe mu cyumweru.
Intego yibanze kwari ukugereranya CagriSema (2,4 mg / 2,4 mg) na semeglutide cyangwa umwanya wa rimwe mu cyumweru munsi yubutaka.Novo Nordisk yatangaje ibyavuye mu igeragezwa rya CagriSema yo kuvura diyabete yo mu cyiciro cya 2, byagaragaje ko indwara ya hypoglycemic ya CagriSema iruta iya semeglutide, kandi hafi 90% by'amasomo yageze ku ntego ya HbA1c.
Amakuru yerekanaga ko usibye ingaruka zikomeye za hypoglycemic, mubijyanye no kugabanya ibiro, inshinge ya CagriSema yarushije cyane semeglutide (5.1%) na cagrilintide (8.1%) hamwe no gutakaza ibiro 15,6%.
Ibiyobyabwenge bishya bya Tirzepatide nicyo cyemewe bwa mbere ku isi GIP / GLP-1 reseptor agonist.Ihuza ingaruka za incretine ebyiri muri molekile imwe yatewe inshuro imwe mucyumweru kandi ni icyiciro gishya cyo kuvura diyabete yo mu bwoko bwa 2.Tirzepatide yemejwe n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) muri Gicurasi 2022 kugira ngo irusheho kurwanya indwara ya glycemic (hashingiwe ku mirire no mu myitozo ngororamubiri) ku bantu bakuze barwaye diyabete yo mu bwoko bwa 2, ubu bikaba byemewe mu muryango w’ubumwe bw’ibihugu by’Uburayi, Ubuyapani ndetse no mu bindi bihugu.
Ku ya 5 Nyakanga, Eli Lilly yatangaje icyiciro cya III ubushakashatsi bwa SURPASS-CN-MONO ku iyandikwa ry’ibizamini by’amavuriro n’ibikorwa byo gutangaza amakuru yo kuvura abarwayi ba diyabete yo mu bwoko bwa 2.SURPASS-CN-MONO nubushakashatsi bwateganijwe, buhumye-buhumyi, bugenzurwa nicyiciro cya gatatu cyateguwe hagamijwe gusuzuma imikorere n’umutekano wa monoterapi ya tirzepatide ugereranije na placebo mu bantu barwaye diyabete yo mu bwoko bwa 2.Ubushakashatsi bwateganyaga gushyiramo abarwayi 200 barwaye diyabete yo mu bwoko bwa 2 batigeze bari ku miti iyo ari yo yose ya antidiabete mu minsi 90 ibanziriza gusura 1 (usibye mu bihe bimwe na bimwe by’amavuriro, nk'uburwayi bukabije, ibitaro, cyangwa kubagwa batoranijwe, mu gihe gito (≤14) iminsi) gukoresha insuline).
Biteganijwe ko diyabete yo mu bwoko bwa 2 izemezwa muri uyu mwaka
Ukwezi gushize, ibisubizo byubushakashatsi bwa SURPASS-AP-Combo byasohotse ku ya 25 Gicurasi mu kinyamakuru cyitwa Nature Medicine.Ibisubizo byagaragaje ko ugereranije na glargine ya insuline, Tirzepatide yerekanye HbA1c nziza no kugabanya ibiro ku baturage b’abarwayi ba diyabete yo mu bwoko bwa 2 mu karere ka Aziya-Pasifika (cyane cyane Ubushinwa): Kugabanuka kwa HbA1c kugera kuri 2,49% no kugabanya ibiro bigera kuri 7.2 kg .
Ikizamini cya Phase 3 cyubuvuzi bwa SURPASS-AP-Combo nubushakashatsi bwa mbere bwa Tirzepatide bwakozwe cyane cyane ku barwayi b’abashinwa barwaye diyabete yo mu bwoko bwa 2, buyobowe na Porofeseri Ji Linong wo mu bitaro by’abaturage bya kaminuza ya Peking.SURPASS-AP-Combo ihuje n'ibyavuye mu bushakashatsi bwakozwe na SURPASS ku isi hose, ibyo bikaba byerekana kandi ko indwara ya diyabete ku barwayi b'Abashinwa ihuye n'iy'abarwayi bo ku isi, ikaba ari yo shingiro ry'ubushakashatsi icyarimwe no guteza imbere imiti mishya. mu Bushinwa ndetse no ku isi, kandi inatanga ibimenyetso bifatika byo guha abarwayi b'Abashinwa amahirwe yo gukoresha imiti ivura diyabete iheruka ndetse no kuyivura mu Bushinwa vuba bishoboka.
Igihe cyo kohereza: Nzeri-18-2023